(Q34205630)

31 July 2017

1 reference

title

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants (English)

1 reference

pneumococcal conjugate vaccine

31 July 2017

1 reference

1 reference

David Goldblatt

5

0 references

Keith P. Klugman

7

object named as

Keith Klugman

1 reference

31 July 2017

4

Ron Dagan

1 reference

31 July 2017

8

Brian Plikaytis

1 reference

31 July 2017

3

George Carlone

1 reference

31 July 2017

6

Helena Käyhty

1 reference

31 July 2017

2

Jay Butler

1 reference

31 July 2017

11

Ih Chang

1 reference

31 July 2017

Luis Jódar

1

1 reference

31 July 2017

George Siber

9

1 reference

31 July 2017

Robert Kohberger

10

1 reference

31 July 2017

Thomas Cherian

12

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

31 July 2017

1 reference

31 July 2017

21

1 reference

31 July 2017

3265-3272

1 reference

31 July 2017

23

1 reference

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Safety, immunogenicity, and efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population: possible implications for optimal use

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Assessing efficacy of Haemophilus influenzae type b combination vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Bridging phase 2 and phase 3 pneumococcal immunologic data for future combination vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

1 reference

7 January 2021

Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Pathogenesis of pneumococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Virulence, immunity, and vaccine related to Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900230-5

7 January 2021

10.1016/S0264-410X(03)00230-5

Identifiers

DOI

1 reference

31 July 2017

1 reference